Abstract 2632: Improved Outcomes of CPR in Rats Model of Myocardial Infarction Treated with Bone Marrow Mesenchymal Stem Cells
Background: Previous studies have demonstrated that bone marrow mesenchymal stem cells (MSCs) improved myocardial function following myocardial infarction (MI). We investigated whether this improved myocardial function persists following the second episodes of global myocardial ischemia and reperfusion (VF and CPR).
Hypothesis: After myocardial infarction, improved myocardial function following the treatment of MSCs persists after the subsequent global myocardial ischemia and reperfusion. It therefore improves the outcome of CPR.
Methods: A thoracotomy was performed under general anesthesia in 18 male Sprague-Dawley rats. MI was induced by ligation of the left anterior descending artery. Four weeks later, animals were randomized to receive 5×106 MSCs marked with PKH26 in phosphate buffer solution (PBS) or a PBS bolus injection into the right femoral vein. Four weeks after injection, ventricular fibrillation (VF) was electrically induced. After 6 min of untreated VF, CPR was performed for 6 min prior to attempted defibrillation. Left ventricular (LV) dp/dt40 (dp/dt40) and LV negative dp/dt (-dp/dt) were measured before inducing VF and at hourly intervals following resuscitation (ROSC).
Results: Significant improvements in dp/dt40 and -dp/dt followed injection of MSCs prior to inducing VF (Table 1⇓). No significant differences in ROSC were observed between the two groups. Following ROSC, myocardial function was significantly better in animals pretreated with MSCs (Table 1⇓). Duration of survival was significantly longer in MSCs-treated animals (64.6±11.1 vs. 38.6±27.3, p=0.046).
Conclusions: Myocardial function and duration of survival after ROSC were significantly improved in MI animals treated with MSCs. The improved myocardial function after MSCs treatment was not compromised by the second protocol of ischemia and reperfusion (VF and CPR).